3'-deamino-3'-hydroxydoxorubicin: substitution of the basic amino group at the C-3' of doxorubicin by a hydroxyl group overcomes recognition of the multidrug resistant P-glycoprotein and limits cardiotoxicity; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 454841 |
CHEMBL ID | 2074806 |
MeSH ID | M0126489 |
Synonym |
---|
5,12-naphthacenedione, 10-((2,6-dideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s-cis)- |
3'-deamino-4'-epi-3'-hydroxydoxorubin |
brn 5205491 |
5,12-naphthacenedione, 7,8,9,10-tetrahydro-10-((2,6-dideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-8-(hydroxyacetyl)-1-methoxy-6,8,11-trihydroxy-, (8s-cis)- |
hydroxydoxorubicin |
(8s-cis)-10-[(2,6-dideoxy-.alpha.-l-lyxo-hexopyranosyl]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione |
hydroxyrubicin |
(7s,9s)-7-[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione |
3'-deamino-3'-hydroxydoxorubicin |
ho-dox |
73113-90-3 |
(7s,9s)-7-[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione |
CHEMBL2074806 |
unii-m61cnw3494 |
m61cnw3494 , |
5,12-naphthacenedione, 10-((2,6-dideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s,10s)- |
5,12-naphthacenedione, 10-((2,6-dideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s-cis)- |
DTXSID00873756 |
Q27283534 |
Excerpt | Reference | Relevance |
---|---|---|
" In mice, the acute LD50 of hydroxyrubicin was about 3-fold higher than that of doxorubicin (79." | ( Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Burke, TG; Perez-Soler, R; Priebe, W; Van, NT, 1993) | 0.29 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
ATP-dependent translocase ABCB1 | Homo sapiens (human) | Km | 2.0000 | 0.0140 | 3.7172 | 10.0000 | AID680887 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytoplasm | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
plasma membrane | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
cell surface | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
membrane | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
apical plasma membrane | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
extracellular exosome | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
external side of apical plasma membrane | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
plasma membrane | ATP-dependent translocase ABCB1 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID680887 | TP_TRANSPORTER: efflux in Doxorubicin resistant K562 cells | 1994 | FEBS letters, Dec-19, Volume: 356, Issue:2-3 | P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 5 (55.56) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (9.09%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |